Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Capricor Therapeutics Inc's Business Segments
Capricor Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | - | - |
Description of Capricor Therapeutics Inc
Capricor Therapeutics Inc. is a clinical-stage biotechnology company headquartered in Los Angeles, California, founded in 200 Capricor Therapeutics is focused on the development of innovative cell-based therapies for the treatment of cardiovascular and other diseases. The company's core technology is based on the mesenchymal stem cells (MSCs).
Capricor Therapeutics has developed a proprietary platform for the isolation, manufacturing, and delivery of MSCs. These cells are derived from the bone marrow, fat tissue, or placenta of healthy donors. The platform also includes a process for culturing MSCs that is designed to maximize their therapeutic potential.
Capricor Therapeutics is currently conducting clinical trials of its lead product candidate, CAP-1002, which is an allogeneic cell therapy consisting of MSCs. CAP-1002 is being evaluated in multiple indications, including Duchenne muscular dystrophy (DMD), cardiac diseases, and pulmonary arterial hypertension. The company has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for CAP-1002 in DMD.
Capricor Therapeutics also has a range of preclinical programs focused on the discovery and development of new cell-based therapies for the treatment of other diseases, including neurological disorders.
In addition to its own research and development efforts, Capricor Therapeutics has collaborations with several academic institutions and industry partners. The company is financially supported by a combination of government grants, private investors, and partnerships.
Overall, Capricor Therapeutics is a biotechnology company that is focused on developing innovative cell-based therapies for the treatment of cardiovascular and other diseases. The company's MSC-based platform technology has the potential to address significant unmet medical needs, and it is currently being evaluated in multiple clinical trials.
Capricor Therapeutics has developed a proprietary platform for the isolation, manufacturing, and delivery of MSCs. These cells are derived from the bone marrow, fat tissue, or placenta of healthy donors. The platform also includes a process for culturing MSCs that is designed to maximize their therapeutic potential.
Capricor Therapeutics is currently conducting clinical trials of its lead product candidate, CAP-1002, which is an allogeneic cell therapy consisting of MSCs. CAP-1002 is being evaluated in multiple indications, including Duchenne muscular dystrophy (DMD), cardiac diseases, and pulmonary arterial hypertension. The company has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for CAP-1002 in DMD.
Capricor Therapeutics also has a range of preclinical programs focused on the discovery and development of new cell-based therapies for the treatment of other diseases, including neurological disorders.
In addition to its own research and development efforts, Capricor Therapeutics has collaborations with several academic institutions and industry partners. The company is financially supported by a combination of government grants, private investors, and partnerships.
Overall, Capricor Therapeutics is a biotechnology company that is focused on developing innovative cell-based therapies for the treatment of cardiovascular and other diseases. The company's MSC-based platform technology has the potential to address significant unmet medical needs, and it is currently being evaluated in multiple clinical trials.
Capricor Therapeutics Inc. is a clinical-stage biotechnology company that is at the forefront of developing and commercializing innovative therapies aimed at addressing unmet medical needs in various health domains. The companys focus is primarily on regenerative medicine, which encompasses a range of novel therapeutic approaches to repair or regenerate tissues, particularly in diseases affecting the cardiovascular system, muscular dystrophy, and fibrotic disorders. Below is an extensive description of the segments, products, and services offered by Capricor Therapeutics.
Segments:
1. Cardiovascular Diseases:
- Capricor Therapeutics is committed to advancing treatments for cardiovascular ailments, leveraging its expertise in regenerative medicine. The company has developed a proprietary cell-based therapy utilizing cardiosphere-derived cells (CDCs). These uniquely versatile cells are derived from heart tissue and are designed to be injected directly into damaged heart regions. The goal of this intervention is to foster regeneration of heart muscle, enhance vascular repair, and improve overall cardiac function.
2. Muscular Dystrophy:
- One of the areas of focus for Capricor is Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration. The companys innovative approach involves the use of Exosomes Therapy, which exploits natural exosomes—tiny vesicles released by cells that play a crucial role in cell communication. This therapy aims at reducing inflammation and promoting muscle cell regeneration specifically for DMD patients, addressing critical aspects of the diseases pathology.
3. Fibrotic Disorders:
- Capricor Therapeutics is also addressing fibrotic disorders, which are characterized by excessive scarring and fibrosis in various tissues, leading to reduced function and organ damage. The company’s CAP-1002 therapy targets such conditions by leveraging CDCs to lessen inflammation, promote tissue repair, and mitigate scarring. This approach aims to restore normal function in affected organs, including the heart, lungs, liver, and kidneys.
Products:
1. CAP-1002 Therapy:
- CAP-1002 is Capricor Therapeutics flagship product and represents a breakthrough in regenerative therapies for heart disease. This cell-based therapy has shown promise in multiple clinical indications including heart failure related to DMD, non-ischemic dilated cardiomyopathy (NIDCM), and acute myocardial infarction (AMI). The therapy’s mechanism involves the injection of CDCs into the heart muscle to stimulate regeneration, improve blood flow, and enhance both functional and structural recovery.
2. Exosomes Therapy:
- This innovative treatment utilizes exosomes derived from CDCs, aimed specifically at treating DMD. The Exosomes Therapy is designed to harness the regenerative properties of these vesicles to deliver bioactive molecules that can reduce muscle inflammation and stimulate regeneration of damaged muscle tissue. The potential for exosome-based therapies extends beyond DMD and signals a broad therapeutic promise in muscle-repair mechanisms.
Services:
1. Clinical Trials:
- Capricor Therapeutics actively conducts clinical trials to evaluate the safety and efficacy of its therapeutic products. The company partners with leading clinical research organizations (CROs) to ensure that trials are rigorously designed and comply with all regulatory requirements. This commitment to high-quality clinical research is essential for advancing new treatment options for patients.
2. Manufacturing:
- Capricor Therapeutics boasts a cutting-edge manufacturing facility dedicated to producing high-quality, consistent cell-based therapies. The facility employs advanced manufacturing techniques to ensure that all products meet stringent regulatory quality and safety standards. This robust manufacturing capability is crucial for scaling up production as the company progresses through clinical development towards potential market introduction.
3. Regulatory Affairs:
- Navigating the complex regulatory environment surrounding cell-based therapies can be challenging. Capricor Therapeutics offers comprehensive regulatory support services to facilitate the path to market for its therapies. The company’s team of experienced regulatory professionals provides expertise in navigating regulatory requirements, guiding the submission processes for product approvals, and helping to establish marketing strategies post-approval.
In summary, Capricor Therapeutics Inc. is dedicated to pioneering therapies that focus on regenerative medicine across multiple disease segments, including cardiovascular diseases, muscular dystrophy, and fibrotic disorders. Their portfolio encompasses advanced therapies like CAP-1002 and Exosomes Therapy, supported by robust clinical trial operations, state-of-the-art manufacturing processes, and expert regulatory guidance. Through these efforts, Capricor aims to provide innovative solutions that address significant medical needs and improve patient outcomes.
Segments:
1. Cardiovascular Diseases:
- Capricor Therapeutics is committed to advancing treatments for cardiovascular ailments, leveraging its expertise in regenerative medicine. The company has developed a proprietary cell-based therapy utilizing cardiosphere-derived cells (CDCs). These uniquely versatile cells are derived from heart tissue and are designed to be injected directly into damaged heart regions. The goal of this intervention is to foster regeneration of heart muscle, enhance vascular repair, and improve overall cardiac function.
2. Muscular Dystrophy:
- One of the areas of focus for Capricor is Duchenne muscular dystrophy (DMD), a severe genetic disorder characterized by progressive muscle degeneration. The companys innovative approach involves the use of Exosomes Therapy, which exploits natural exosomes—tiny vesicles released by cells that play a crucial role in cell communication. This therapy aims at reducing inflammation and promoting muscle cell regeneration specifically for DMD patients, addressing critical aspects of the diseases pathology.
3. Fibrotic Disorders:
- Capricor Therapeutics is also addressing fibrotic disorders, which are characterized by excessive scarring and fibrosis in various tissues, leading to reduced function and organ damage. The company’s CAP-1002 therapy targets such conditions by leveraging CDCs to lessen inflammation, promote tissue repair, and mitigate scarring. This approach aims to restore normal function in affected organs, including the heart, lungs, liver, and kidneys.
Products:
1. CAP-1002 Therapy:
- CAP-1002 is Capricor Therapeutics flagship product and represents a breakthrough in regenerative therapies for heart disease. This cell-based therapy has shown promise in multiple clinical indications including heart failure related to DMD, non-ischemic dilated cardiomyopathy (NIDCM), and acute myocardial infarction (AMI). The therapy’s mechanism involves the injection of CDCs into the heart muscle to stimulate regeneration, improve blood flow, and enhance both functional and structural recovery.
2. Exosomes Therapy:
- This innovative treatment utilizes exosomes derived from CDCs, aimed specifically at treating DMD. The Exosomes Therapy is designed to harness the regenerative properties of these vesicles to deliver bioactive molecules that can reduce muscle inflammation and stimulate regeneration of damaged muscle tissue. The potential for exosome-based therapies extends beyond DMD and signals a broad therapeutic promise in muscle-repair mechanisms.
Services:
1. Clinical Trials:
- Capricor Therapeutics actively conducts clinical trials to evaluate the safety and efficacy of its therapeutic products. The company partners with leading clinical research organizations (CROs) to ensure that trials are rigorously designed and comply with all regulatory requirements. This commitment to high-quality clinical research is essential for advancing new treatment options for patients.
2. Manufacturing:
- Capricor Therapeutics boasts a cutting-edge manufacturing facility dedicated to producing high-quality, consistent cell-based therapies. The facility employs advanced manufacturing techniques to ensure that all products meet stringent regulatory quality and safety standards. This robust manufacturing capability is crucial for scaling up production as the company progresses through clinical development towards potential market introduction.
3. Regulatory Affairs:
- Navigating the complex regulatory environment surrounding cell-based therapies can be challenging. Capricor Therapeutics offers comprehensive regulatory support services to facilitate the path to market for its therapies. The company’s team of experienced regulatory professionals provides expertise in navigating regulatory requirements, guiding the submission processes for product approvals, and helping to establish marketing strategies post-approval.
In summary, Capricor Therapeutics Inc. is dedicated to pioneering therapies that focus on regenerative medicine across multiple disease segments, including cardiovascular diseases, muscular dystrophy, and fibrotic disorders. Their portfolio encompasses advanced therapies like CAP-1002 and Exosomes Therapy, supported by robust clinical trial operations, state-of-the-art manufacturing processes, and expert regulatory guidance. Through these efforts, Capricor aims to provide innovative solutions that address significant medical needs and improve patient outcomes.